

## **MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose's Electronic Dry Powder Inhaler**

MONMOUTH JUNCTION, N.J., and AUCKLAND, NEW ZEALAND, January 6, 2009 - MicroDose Technologies Inc. (MicroDose) and Nexus6 today announced that they have entered into a collaboration to investigate the application of Nexus6's SmartinhalerLive™ technology with MicroDose's next generation electronic dry powder inhaler (DPI). Under the terms of the agreement, MicroDose will fund the development of prototypes based upon MicroDose's inhaler platform and incorporating Nexus6's SmartinhalerLive™ technology. MicroDose will receive an option for an exclusive license to the SmartinhalerLive™ platform for certain fields of use.

The aim of the investigation is to demonstrate the ability to wirelessly upload dosing and compliance information from the inhaler to a web-based server for data management and reporting. The SmartinhalerLive technology, providing global roaming wireless, is a natural extension of MicroDose's electronic inhaler features and will facilitate better communication between the physician, patient and pharmaceutical company to improve all aspects of care.

The combined system would have benefits in both the clinical trials setting and with in-market products. By improving compliance through reminder features, and through real-time tracking of compliance, patient safety and clinical trial data management are improved. Improved control and monitoring of compliance can significantly reduce the number of patients enrolled per Phase II or Phase III clinical studies. In marketed products, the system represents a move to more personalized care, giving a better understanding of drug usage and patient response to therapy, and improved compliance and adherence.

Mr. Michael J. Martin VP of Business Development and Licensing of MicroDose indicated that "the combination of Nexus6 Technology and MicroDose's dry powder inhaler will insure a continuous flow of "real time" clinical information which will benefit physicians, patients and pharmaceutical companies. "

David Evans, CEO of Nexus6 said "this partnership between Nexus6 and MicroDose will enable the drug delivery marketplace to access leading edge data collection and transmission capabilities, thereby increasing pharmaceutical adherence, improving patient well-being and reducing overall health care costs".

### **About the MicroDose DPI**

The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance versus other inhalers, for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture. Microdose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

### **About MicroDose Technologies**

MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery and specialty pharmaceuticals company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies and products for the pharmaceutical and biotechnology industries.

MicroDose's partnered programs include; multi-product development and licensing agreements with Merck and Co. and Novartis, the development of an inhaled insulin product through

MicroDose's QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense, in collaboration with the University of Pittsburgh. MicroDose is also conducting internal development programs for products employing its inhaler technology, and for combination oral dosage products employing its PolyCap™ technology in the areas of diabetes, hypertension and hyperlipidemia. For more information visit us at <http://www.microdose-tech.com>

**About Nexus6 and SmartinhalerLive™**

Nexus6 Limited is a privately held New Zealand based developer and manufacturer of solutions to increase patient adherence to respiratory medications, leading to improved disease management and reduced healthcare costs.

Nexus6 SmartinhalerLive™ devices monitor and report patients' medication usage to their healthcare partners, and are used in pharmaceutical clinical trials and respiratory disease management applications for chronic obstructive pulmonary disease, asthma and cystic fibrosis.

SmartinhalerLive™ uses wireless communications technology to provide real time data collection and reporting from drug delivery devices.

**Contacts:**

For MicroDose Technologies:

Scott Fleming, Sr. Vice President, Sales & Marketing

Tel: (732) 355-2114 E: [sfleming@microdose-tech.com](mailto:sfleming@microdose-tech.com)

For Nexus6:

Garth Sutherland, Chief Operating Officer

Tel: (937) 274 2111 ext 104 E: [garths@smartinhaler.com](mailto:garths@smartinhaler.com)